The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | VR-CAP beats R-CHOP for frontline MCL
Tadeusz Robak, MD, PhD, of the Medical University of Lodz, Lodz, Poland, discusses the Phase III LYM-3002 trial (NCT00722137) comparing the efficacy and safety of frontline VR-CAP (rituximab, cyclophosphamide, doxorubicin, bortezomib and prednisone) vs. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) in newly diagnosed mantle cell lymphoma (MCL) patients who were ineligible for transplantation. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Robak concludes that in MCL patients who are not suitable for transplantation, VR-CAP appears to provide a benefit vs R-CHOP in terms of PFS and CR rates.
